You are here

Article Text

Article menu
Download PDFPDF
Brief communication
Plasma thymic stromal lymphopoietin (TSLP) in adults with non-severe asthma: the EGEA study
  1. Bakari Ibrahim1,
  2. Djamal Achour2,
  3. Farid Zerimech2,
  4. Patricia de Nadai3,
  5. Valerie Siroux4,
  6. Anne Tsicopoulos3,
  7. Régis Matran5,
  8. Vanessa Granger6,7,
  9. Rachel Nadif1
  1. 1 Université Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, Equipe d'Epidémiologie Respiratoire Intégrative, CESP, Paris, France
  2. 2 Université Lille, CHU Lille, Institut Pasteur de Lille, EA 4483, IMPECS, Lille, France
  3. 3 Université Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017-CIIL-Centre d'Infection et d'Immunité de Lille, F-59000 Lille, France
  4. 4 Université Grenoble Alpes, Inserm, CNRS, Team of Environmental Epidemiology Applied to Reproduction and Respiratory Health, IAB, Grenoble, France
  5. 5 Université Lille, CHU Lille, Institut Pasteur de Lille, ULR 4483, Lille, France
  6. 6 Inserm, Inflammation microbiome immunosurveillance, Université Paris-Saclay, Paris, France
  7. 7 UF autoimmunité Hypersensibilités et Biothérapies, APHP, HUPNVS, Hôpital Bichat, Paris, France
  1. Correspondence to Mr Bakari Ibrahim, Epidémiologie Respiratoire Intégrative, CESP, Villejuif 94800, France; bakari.ibrahim{at}inserm.fr

Abstract

Thymic stromal lymphopoietin (TSLP), a cytokine involved in severe asthma treatment, was never studied in non-severe asthma.

Among 969 adults from a large epidemiological study, cross-sectional analyses showed that plasma TSLP levels were associated with increased age and BMI, male sex, smoking and high TSLP levels (one IQR increase) with current asthma and poor lung function. High TSLP levels were also associated with persistence of asthma attacks (aOR=2.14 (95% CI 1.23 to 3.72)) and dyspnoea (aOR=2.71 (95% CI 1.39 to 5.28)) 10 years later.

Our results suggest that TSLP could be a cytokine of interest in non-severe asthma, and its determinants of circulating levels could be considered in asthma management.

  • Asthma
  • Asthma Epidemiology
  • Cytokine Biology

http://dx.doi.org/10.1136/thorax-2022-219192

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Twitter @IbrBakari

    • Contributors BI and RN were involved in the conception, hypotheses delineation and design of theanalysis strategy of the study. FZ, PdN, AT, DA and RM were involved in TSLP measurement and interpretation. RM, RN and VS were involved in the acquisition of EGEA asthma and lung function data. BI and RN analysed the data and performed statistical analyses. BI and RN wrote the paper. FZ, DA, PdN, AT, VS, RM and VG reviewed the paper and revised it critically. All authors approved the final version of the manuscript.

    • Funding This work was funded by the French National Research Program for Environmental and Occupational Health of Anses (EST/2017/1/158) and the region Hauts-de-France.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.